Disease Overview：Immune Thrombocytopenia（ITP）
Immune thrombocytopenia (ITP) is an autoimmune hematologic disorder characterized by isolated thrombocytopenia—platelet counts below 100 × 10⁹/L—without evidence of other causes such as malignancy, infection, or drug-induced cytopenia. In ITP, autoantibodies target platelet glycoproteins (most commonly GPIIb/IIIa), leading to accelerated platelet clearance by the reticuloendothelial system and impaired megakaryocyte maturation. Clinical presentation ranges from asymptomatic thrombocytopenia to mucocutaneous bleeding (e.g., petechiae, epistaxis) or, rarely, life-threatening hemorrhage. Diagnosis relies on exclusion criteria per international guidelines (e.g., ASH, IWG), supported by peripheral blood smear, bone marrow examination when indicated, and serologic testing. First-line therapy typically includes corticosteroids or intravenous immunoglobulin (IVIG); second-line options encompass thrombopoietin receptor agonists (e.g., eltrombopag, romiplostim), rituximab, splenectomy, or newer agents like fostamatinib.
China offers distinct advantages for ITP management: its leading hematology centers—many affiliated with top-tier universities—employ internationally trained specialists with extensive experience in refractory and chronic ITP. Advanced diagnostics include flow cytometry–based platelet autoantibody detection and next-generation sequencing for clonal hematopoiesis assessment. High-volume centers report sustained response rates exceeding 70% at 12 months with TPO-RAs and demonstrate growing expertise in minimally invasive laparoscopic splenectomy. Treatment costs in China are typically 40–60% lower than in the US or Western Europe, without compromising clinical standards or regulatory oversight (NMPA-approved biologics and generics). As a dedicated medical tourism agency, we facilitate seamless access for international patients: verifying hospital credentials, coordinating appointments with ITP-specialized hematologists, providing itemized, transparent pricing in advance, arranging visa support, translation services, and post-treatment follow-up—all under one coordinated care pathway.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Immune Thrombocytopenia (ITP)
Non-Surgical / Conservative / Medication Options
*Target criteria:* Platelet count < 30×10⁹/L with bleeding, or < 10×10⁹/L asymptomatic; first-line for newly diagnosed or chronic ITP.
- •Corticosteroids (Prednisone)
- *Cost:* ¥15–¥30/day → $2.10–$4.20 USD/day - *Lab monitoring (CBC weekly × 4):* ¥80/test → $11.20 USD - *Liver/kidney function panel (baseline + week 2):* ¥220 → $30.80 USD
- •IVIG (Intravenous Immunoglobulin)
- *Dose:* 1 g/kg × 1–2 days - *Drug cost (10 g vial):* ¥680–¥920 → $95–$129 USD/vial (2–4 vials typical) - *Infusion fee + nursing:* ¥350 → $49 USD
- •Thrombopoietin Receptor Agonists (TPO-RAs)
- *Eltrombopag (25 mg tablet):* ¥1,280/month → $179 USD/month - *Romiplostim (250 µg SC injection):* ¥2,450/dose → $343 USD/dose (weekly × 4, then monthly) - *LFT monitoring (monthly × 3):* ¥120 × 3 = $50 USD
Surgical / Procedural / Interventional Options
*Eligibility:* Refractory chronic ITP (≥12 months), platelets < 20×10⁹/L despite ≥2 lines, no contraindications to splenectomy.
- •Laparoscopic Splenectomy
- CBC, coagulation panel, LDH, reticulocyte count: ¥320 → $45 USD - Abdominal ultrasound + chest X-ray: ¥260 → $36 USD - Pneumococcal/Meningococcal/Hib vaccination (required): ¥420 → $59 USD - *Procedure cost (Grade 3A hospital, inclusive of anesthesia, OR, 3-day stay):* ¥28,000–¥36,000 → $3,920–$5,040 USD
Special / Complex Condition Options
- •Rituximab (anti-CD20 monoclonal antibody)
- *Dose:* 375 mg/m² × 4 weekly infusions - *Drug cost (100 mg vial):* ¥1,850 → $259 USD/vial (4–6 vials) - *Infusion + observation (4 sessions):* ¥1,200 → $168 USD
- •High-dose Dexamethasone (HD-DXM)
- *Drug + monitoring (CBC, glucose, BP):* ¥220/cycle → $31 USD/cycle
Quick Selection Guide
- •Newly diagnosed adult (<60 y, no comorbidities): Start with prednisone + monitoring ($150–$200 total).
- •Elderly (>70 y) or diabetic/hypertensive: Prefer IVIG short course ($150–$300) over prolonged steroids.
- •Chronic ITP, moderate budget ($500–$1,500/year): Eltrombopag — lowest long-term cost, oral convenience.
- •Refractory, severe bleeding, adequate budget: Splenectomy — curative intent, one-time cost (~$4,500), avoids lifelong drug dependency.
- •TPO-RA failure + high-risk comorbidities (e.g., heart failure): Rituximab — avoids surgery and steroid toxicity; $1,200–$1,800 total.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Immune Thrombocytopenia Medical Vacation Packages
Curated transparent all-inclusive packages combining Immune Thrombocytopenia treatment with China top medical destinations:
